Nike faces analyst downgrade as Oscar Health gets upgraded, according to Wall Street’s latest calls

Wall Street’s latest batch of top analyst research calls included a downgrade for Nike and an upgrade for Oscar Health, according to Yahoo Finance’s roundup of morning market-moving notes. The updates reflect how quickly sentiment can shift when analysts reassess growth outlooks, valuation, or near-term execution risk across very different parts of the consumer economy.

For Nike, the call was framed as a downgrade, meaning the analyst lowered its rating relative to the stock’s expected performance. The research note also suggests a change in how the analyst views fundamentals going forward, though the Yahoo roundup did not provide additional detail in the information available here, such as the specific reasons, the firm behind the downgrade, or any changes to price targets.

On the healthcare side, Oscar Health was upgraded in the same roundup. An upgrade generally indicates improved expectations, such as a better view of underwriting performance, member growth, or the insurer’s path to profitability. As with Nike, the available information does not include the underlying thesis, the analyst’s target price, or the specific metrics driving the rating change.

These “top calls” pieces often circulate because they can influence trading at the open, particularly when they come from firms that are closely followed by institutional investors and retail brokerage clients. Even when the new rating is not immediately accompanied by hard new disclosures from the companies themselves, the market frequently reacts to the directional announcement of what Wall Street believes is more likely next for earnings power.

Nike operates in a retail and consumer environment where demand trends, promotional activity, and inventory management can swing results quarter to quarter. In that context, analyst downgrades typically point to some combination of margin pressure risk, weaker-than-expected sales durability, or uncertainty around how fast the company can convert brand momentum into earnings growth. At the same time, the company’s performance can also be shaped by product cycle execution and how effectively it manages supply and pricing.

Oscar Health, by contrast, sits in the insurance sector where the company’s performance can hinge on medical cost trends, member behavior, and the pace of improvements to its operating model. Analyst upgrades in health insurance are usually tied to expectations that costs will moderate, risk adjustment and pricing will remain favorable, or that the insurer can scale without sacrificing profitability.